Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Sales Market Report 2024
Market Analysis and InsightsGlobal Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes.
Due to the COVID-19 pandemic, the global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market size is estimated to be worth US$ 9040.4 million in 2024 and is forecast to a readjusted size of US$ 10600 million by 2034 with a CAGR of 2.3% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Sitagliptin accounting for % of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
The United States Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors include Eli Lilly, Glaxo Smith Kline, Boehringer, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi and Novo Nordisk, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Scope and Market Size
The global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Sitagliptin
Saxagliptin
Vildagliptin
Linagliptin
Hospital
Clinic
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Eli Lilly
Glaxo Smith Kline
Boehringer
Bristol-Myers Squibb
Pfizer
AstraZeneca
Sanofi
Novo Nordisk
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes.
Due to the COVID-19 pandemic, the global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market size is estimated to be worth US$ 9040.4 million in 2024 and is forecast to a readjusted size of US$ 10600 million by 2034 with a CAGR of 2.3% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Sitagliptin accounting for % of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
The United States Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors include Eli Lilly, Glaxo Smith Kline, Boehringer, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi and Novo Nordisk, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Scope and Market Size
The global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Sitagliptin
Saxagliptin
Vildagliptin
Linagliptin
Segment by Application
Hospital
Clinic
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Eli Lilly
Glaxo Smith Kline
Boehringer
Bristol-Myers Squibb
Pfizer
AstraZeneca
Sanofi
Novo Nordisk
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices